证券代码：002286 证券简称：保龄宝 公告编号：2025-040 保龄宝生物股份有限公司 关于召开公司 2025 年第二次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 保龄宝生物股份有限公司（以下简称"公司"）第六届董事会第十一次会议于 开公司 2025 年第二次临时股东会，现将本次股东会的有关事项公告如下： 一、召开会议基本情况 （一）股东会届次：2025 年第二次临时股东会。 （二）会议召集人：保龄宝生物股份有限公司第六届董事会。 （三）会议召开的合法、合规性：公司第六届董事会第十一次会议审议通过 了《关于召开公司 2025 年第二次临时股东会的议案》，决定于 2025 年 6 月 26 日上午 9 点召开公司 2025 年第二次临时股东会。本次股东会的召集程序符合有 关法律法规和公司章程的规定。 （四）会议召开的日期、时间： 年 6 月 26 日 9:15-9:25，9:30-11:30 和 13:00-15:00；通过深圳证券交易所互联网 投票系统进行投票的时间为 2025 年 6 月 26 日上午 9：15 至下午 15：00 ...

Core Viewpoint - The company, Baolingbao Biological Co., Ltd., has proposed changes to its business scope and amendments to its articles of association to meet operational development needs [1][2]. Business Scope Changes - The business scope has been expanded to include the production and sales of pharmaceuticals, as well as the import and export of drugs, which were not included in the previous scope [1][2]. - The previous business scope included starch sugar, other foods, food additives, health foods, medicinal auxiliary materials, feed additives, beverage research and development, production, and sales, as well as pre-packaged food wholesale and grain purchase and sales [1][2]. Amendments to Articles of Association - The amendments to the articles of association reflect the changes in the business scope, ensuring compliance with relevant laws and regulations [3][4]. - The board of directors has outlined the approval authority for significant transactions, including asset purchases or sales, external investments, and guarantees, which must be approved by the board [5][6]. Approval Process - The proposed changes will be submitted to the shareholders' meeting for approval, and the management team will be authorized to handle the necessary business registration changes [7][8]. - The company emphasizes that all amendments will be subject to the final approval of the relevant regulatory authorities [9].

证券代码：002286 证券简称：保龄宝 公告编号：2025-038 保龄宝生物股份有限公司 关于向 2025 年限制性股票激励计划激励对象 首次授予限制性股票的公告 公司董事会及全体成员保证公告内容的真实、准确和完整，不存在虚假记 录、误导性陈述或者重大遗漏。 重要内容提示： 鉴于《保龄宝生物股份有限公司 2025 年限制性股票激励计划（草案）》（以 下简称"本次激励计划"、"《激励计划（草案）》"）规定的限制性股票首次授予 条件已成就，根据保龄宝生物股份有限公司（以下简称"公司"）2024 年年度股 东会对公司董事会的授权，公司于 2025 年 6 月 9 日召开第六届董事会第十一次 会议审议通过了《关于向 2025 年限制性股票激励计划激励对象首次授予限制性 股票的议案》，同意以 2025 年 6 月 9 日为首次授予日，以 3.92 元/股的价格向符 合条件的50名激励对象授予1,035.00万股限制性股票。现将有关事项公告如下： 一、股权激励计划简述及已履行的程序 （一）本次激励计划简述 本次激励计划已经由公司 2025 年 4 月 24 日召开的第六届董事会第九次会议 以及 2025 年 5 月 ...

（截止授予日） 一、 限制性股票激励计划分配情况总表 保龄宝生物股份有限公司（以下简称"公司"）首次授予限制性股票的激励对象 共 50 人，各激励对象间的分配情况如下表所示： | 姓名 | 职务 | 获授的限制性股 | 占首次授予限 制性股票总量 | 占本激励计划公告 | | --- | --- | --- | --- | --- | | | | 票数量（万股） | 的比例 | 日总股本的比例 | | 王强 | 董事、总经理 | 65 | 6.28% | 0.18% | | 李洪波 | 董事、副董事长 | 50 | 4.83% | 0.14% | | 刘峰 | 董事、常务副总经理 | 50 | 4.83% | 0.14% | | 秦翠萍 | 董事 | 45 | 4.35% | 0.12% | | 李霞 | 副总经理 | 45 | 4.35% | 0.12% | | 周瑜 | 财务总监 | 40 | 3.86% | 0.11% | | 朱哲 | 董事会秘书 | 40 | 3.86% | 0.11% | | 其他核心管理人员、核心业务 | 人） 人员、核心技术人员（43 | 700 | 67.63% | 1.89 ...

北京雍行律师事务所 关于保龄宝生物股份有限公司 2025 年限制性股票激励计划首次授予相关事项 之 法律意见书 二〇二五年六月 | 一、本次授予的批准与授权 4 | | --- | | 二、本次授予的具体情况 6 | | 三、结论意见 7 | 释义 除非另有说明或上下文文意另有所指，本法律意见书中相关词语具有以下特 定含义： | 保龄宝、公司 | 指 | 保龄宝生物股份有限公司 | | --- | --- | --- | | 本次激励计划、本激励 | 指 | 保龄宝生物股份有限公司 年限制性股票激励计划 2025 | | 计划 | | | | 本次授予 | 指 | 保龄宝生物股份有限公司2025年限制性股票激励计划首 次授予 | | 《激励计划（草案）》、 | 指 | 《保龄宝生物股份有限公司2025年限制性股票激励计划 | | 激励计划草案 | | （草案）》 | | 《考核管理办法》 | 指 | 《保龄宝生物股份有限公司2025年限制性股票激励计划 | | | | 实施考核管理办法》 | | 《公司法》 | 指 | 《中华人民共和国公司法》 | | 《证券法》 | 指 | 《中华人民共和国证券法》 | | ...

保龄宝生物股份有限公司董事会 薪酬与考核委员会关于公司 2025 年限制性股票激励计划首次 授予激励对象名单（截止授予日）的核查意见 保龄宝生物股份有限公司（以下简称"公司"）于 2025 年 6 月 9 日召开了第六 届董事会薪酬与考核委员会第四次会议，依据《中华人民共和国公司法》(以下简称 "《公司法》")、《中华人民共和国证券法》(以下简称"《证券法》")、《上市 公司股权激励管理办法》(以下简称"《管理办法》")等相关法律法规、规范性文件 和《公司章程》的有关规定，对公司《保龄宝生物股份有限公司 2025 年限制性股票 激励计划（草案）》(以下简称 "本次激励计划")首次授予激励对象名单（截止授 予日）进行了核查，发表核查意见如下: 公司董事会薪酬与考核委员会认为，公司实施激励计划及向激励对象授予限制 性股票，有利于进一步完善公司治理结构，健全公司激励制度，有利于公司的持续发 展，不会损害公司及全体股东的利益。 综上，董事会薪酬与考核委员会同意限制性股票的授予日为 2025 年 6 月 9 日， 以 3.92 元/股的授予价格向符合授予条件的 50 名激励对象授予 1,035 万股限制性股 保龄宝生物 ...

证券代码：002286 证券简称：保龄宝 公告编号：2025-037 保龄宝生物股份有限公司 第六届董事会第十一次会议决议公告 公司董事会及全体成员保证公告内容的真实、准确和完整，不存在虚假记 录、误导性陈述或者重大遗漏。 一、会议召开情况 保龄宝生物股份有限公司（以下简称"公司"）关于召开第六届董事会第十 一次会议的通知于2025年6月6日以电子邮件的方式发出，会议于2025年6月9日 以通讯表决的方式召开。会议应出席董事9人，实际出席董事9人。会议召集、 召开程序符合《公司法》和《公司章程》等法规的规定。 二、会议审议情况 1、会议以 5 票同意，0 票反对，0 票弃权，审议通过《关于向 2025 年限制性 股票激励计划激励对象首次授予限制性股票的议案》，关联董事李洪波、王强、 刘峰、秦翠萍回避表决。 根据《上市公司股权激励管理办法》、《保龄宝生物股份有限公司2025年 限制性股票激励计划（草案）》的有关规定以及公司2024年年度股东会对公司 董事会的授权，公司2025年限制性股票激励计划规定的授予条件已经成就，拟 将首次授予日确定为2025年6月9日，以3.92元/股的价格向符合条件的50名激励 对象授 ...

Core Insights - The functional sugar industry in China is experiencing a boom driven by national policy support and increasing health consumption demand, but it also faces challenges from international trade tensions and domestic competition [1][5][6] Industry Overview - Yucheng, known as the "Capital of Functional Sugar" in China, produces 35% of the global and 60% of the domestic functional sugar market share, with major companies like Baolingbao and Bailong Chuangyuan leading the industry [2][3] - The city has an annual production capacity of 1.5 million tons of various functional sugar products, leveraging local corn resources for production [2][3] Product Categories - Functional sugars are categorized into three types: functional sugar alcohols, functional dietary fibers, and functional oligosaccharides, with products like erythritol and xylitol being prominent examples [3][4] - New products such as trehalose are being developed for medical applications, including wound healing and vaccine stabilization [3] Market Dynamics - The rise of "zero-sugar" beverages has significantly increased the demand for erythritol, leading to a surge in production capacity that outstripped global demand, resulting in a price drop and industry consolidation [5][6] - Erythritol prices peaked at 40,000 yuan per ton before falling below cost price due to oversupply, leading to financial difficulties for many companies [6] Financial Performance - Companies like Baolingbao and Bailong Chuangyuan are beginning to see a recovery in profits, with Baolingbao reporting a net profit of 110 million yuan in 2024, a 106% increase year-on-year [6] Trade Challenges - The industry faces uncertainties due to anti-dumping investigations in the US and EU, with potential tariffs ranging from 3.29% to 233.3% on Chinese erythritol products [6][7] Strategic Adjustments - Companies are shifting focus to domestic markets while exploring new international markets, adapting their sales strategies to balance domestic and export demands [7] - New product development is a priority, with companies planning to increase production of high-demand products like allulose and tagatose [7][9] Future Outlook - The allulose market is expected to grow significantly, with projections estimating a market size of $200 million in 2024 and $500 million by 2030 [8][9] - Companies are actively expanding their allulose production capacities, anticipating regulatory approvals for new products in the near future [9][10]

Core Viewpoint - The major shareholder of Baolingbao, Ningbo Baopu Futong Asset Management Center, plans to reduce its stake by up to 3% through block trading and centralized bidding from June 24 to September 23, 2023, despite the company's recent performance recovery [2][7]. Shareholder Reduction - Baolingbao announced that Baopu Futong will reduce its holdings by no more than 3% of the total shares, with a maximum of 2% (7.3953 million shares) through block trading and 1% (3.6977 million shares) through centralized bidding [2][7]. - Since 2020, Baolingbao has disclosed seven announcements regarding Baopu Futong's share reductions, with six plans not executed. The only successful reduction was in July 2020, where 3.85% was reduced from a planned 5.4% [2]. Financial Performance - In 2024, Baolingbao's revenue was approximately 2.402 billion yuan, a decrease of 4.84% year-on-year, primarily due to adjustments in product structure and marketing strategies [4]. - The core business segments, including prebiotics, dietary fiber, and sugar-reducing sweeteners, showed significant recovery, with revenues of approximately 335 million yuan (up 16.02%), 238 million yuan (up 14.52%), and 516 million yuan (up 29.73%) respectively [4]. - In Q1 2025, Baolingbao achieved a revenue of approximately 685 million yuan, a year-on-year increase of 24.23%, and a net profit attributable to shareholders of approximately 50.36 million yuan, up 117.35% [6][7]. Market Dynamics - The European market for Baolingbao's erythritol products has seen an increase in both volume and price following the EU's anti-dumping investigation [5]. - The company is focusing on high-end products such as prebiotics, dietary fiber, and sugar-reducing sweeteners, adopting a business model that emphasizes small-batch, high-value, and differentiated orders [8]. Management Changes - Baolingbao has experienced frequent changes in its executive team, with several high-level resignations in early 2023. Analysts suggest that while some departures may be due to personal reasons, others could relate to operational adjustments [9]. - The competitive landscape for sugar-reducing sweeteners includes major players like Jinhe Industrial and Sanyuan Biological, which have advantages in product development and market channels [9][10]. R&D and Future Outlook - Baolingbao is increasing its investment in allulose, with a technical transformation project set to produce over 5,000 tons annually, and a second-phase expansion project planned for 20,000 tons [10]. - Despite the growth in the sugar-reducing sweetener market, industry analysts express caution regarding the pace of product innovation and the competitive gap between Baolingbao and leading companies [10].